American Snuff Co. Recalls Kodiak Premium Wintergreen Tobacco

Business by 2FIRSTS.ai

Dec.19.2023

American Snuff Co. Recalls Kodiak Premium Wintergreen Tobacco

American Snuff Co., ASC voluntarily recalls batches of Kodiak Premium Wintergreen Longcut Tobacco sold in 18 states due to potential metallic contamination.

According to a report from Tobaccoreporter, American Snuff Co., ASC, is voluntarily recalling certain batches of Kodiak Premium Wintergreen Longcut Tobacco that were produced at their factory in Clarksville, Tennessee and sold in 18 states.

ASC has reported this voluntary recall incident to the US Food and Drug Administration and is working with the agency to address the issue.

According to a notice on the company's website, ASC has initiated a recall after discovering that certain batches of its products may contain metal foreign objects that may or may not be visible to consumers. The recall was prompted by a routine inspection which found issues with the production equipment, leading to wear and tear between metal components. This wear and tear could potentially result in metal fragments coming into contact with tobacco during the production process. So far, no products containing these foreign objects have been found, and the company has not received any consumer complaints or reports of consumer harm.

ASC's other products have not been affected, including other varieties of Kodiak, Grizzly, Hawken, and Cougar smokeless tobacco products, as well as all loose leaf, twisted, dry snuff, and plug products.

The American Smokeless Tobacco Company (ASC) has instructed wholesalers and retailers to separate the recalled Kodiak Premium Wintergreen Longcut tobacco from their inventory.

References:

[1] American Snuff Recalls Kodiak Premium Wintergreen

Also Read:

[1] Russian Prosecutor Requests Court to Shut Down Nasal Snuff Website

[2] FDA Authorizes Copenhagen Classic Snuff as Modified Risk Tobacco Product

#North America #United States #Traditional tobacco #Products

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months

The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.

Oct.20 by 2FIRSTS.ai

2Firsts Investigation | China–U.S. E-cigarette Shipping Costs Surge: Sea Freight Up Over 200%, Air Cargo Inspection Rate Exceeds 50%

Since late July, China–U.S. e-cigarette shipping costs have surged — sea freight up over 200%, air cargo inspection rates exceeding 50%. 2Firsts investigates the key drivers behind the spike and how the industry is responding.

Oct.15

Heaven Gifts to Cease Sale of Flavored E-Cigarettes in California as Part of Settlement with NJOY: Court to Issue Permanent Injunction.

Heaven Gifts agrees to stop selling flavored disposable e-cigarettes in California as part of settlement with NJOY.

Oct.13 by 2FIRSTS.ai

Abu Dhabi Closes Two Stores Near Schools Over Vape Sales Violations

The Abu Dhabi Business Registration Authority (ADRA) closed two commercial establishments and issued 61 warnings and 18 fines to outlets near schools for violating tobacco and e-cigarette sales regulations, according to the Emirates News Agency (WAM). The measures aim to protect youth and ensure compliance with the Federal Anti-Tobacco Law.